Dario A A Vignali
Overview
Explore the profile of Dario A A Vignali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
196
Citations
19678
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Aggarwal V, Workman C, Vignali D
Nat Immunol
. 2023 Jul;
24(9):1415-1422.
PMID: 37488429
Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor that is highly expressed by exhausted T cells. LAG-3 is a promising immunotherapeutic target, with more than 20 LAG-3-targeting therapeutics in...
22.
Wu V, Yung B, Faraji F, Saddawi-Konefka R, Wang Z, Wenzel A, et al.
Nat Immunol
. 2023 Jun;
24(8):1318-1330.
PMID: 37308665
Immune checkpoint blockade (ICB) targeting PD-1 and CTLA-4 has revolutionized cancer treatment. However, many cancers do not respond to ICB, prompting the search for additional strategies to achieve durable responses....
23.
Chen C, Kumbhar R, Wang H, Yang X, Gadhave K, Rastegar C, et al.
bioRxiv
. 2023 Jun;
PMID: 37293032
The spread of prion-like protein aggregates is believed to be a common driver of pathogenesis in many neurodegenerative diseases. Accumulated tangles of filamentous Tau protein are considered pathogenic lesions of...
24.
Bender M, McPherson A, Phelps C, Pandey S, Laughlin C, Shapira J, et al.
Cell
. 2023 Apr;
186(9):1846-1862.e26.
PMID: 37028428
The use of probiotics by cancer patients is increasing, including among those undergoing immune checkpoint inhibitor (ICI) treatment. Here, we elucidate a critical microbial-host crosstalk between probiotic-released aryl hydrocarbon receptor...
25.
Onkar S, Cui J, Zou J, Cardello C, Cillo A, Rafid Uddin M, et al.
Nat Cancer
. 2023 Apr;
4(4):582.
PMID: 37012402
No abstract available.
26.
Gocher-Demske A, Cui J, Szymczak-Workman A, Vignali K, Latini J, Pieklo G, et al.
Nat Immunol
. 2023 Mar;
24(5):841-854.
PMID: 36928412
Regulatory T (T) cells are an immunosuppressive population that are required to maintain peripheral tolerance and prevent tissue damage from immunopathology, via anti-inflammatory cytokines, inhibitor receptors and metabolic disruption. Here...
27.
Onkar S, Cui J, Zou J, Cardello C, Cillo A, Rafid Uddin M, et al.
Nat Cancer
. 2023 Mar;
4(4):516-534.
PMID: 36927792
T cell-centric immunotherapies have shown modest clinical benefit thus far for estrogen receptor-positive (ER) breast cancer. Despite accounting for 70% of all breast cancers, relatively little is known about the...
28.
Onkar S, Carleton N, Lucas P, Bruno T, Lee A, Vignali D, et al.
Cancer Discov
. 2023 Jan;
13(1):23-40.
PMID: 36620880
Significance: Although there are currently over 200 ongoing clinical trials testing immunotherapeutics, such as immune-checkpoint blockade agents, these are largely restricted to the triple-negative and HER2+ subtypes and primarily focus...
29.
Wang W, Wu S, Cen Z, Zhang Y, Chen Y, Huang Y, et al.
Cell Rep
. 2022 Nov;
41(5):111582.
PMID: 36323258
In "healthy" tumor cells, phosphatidylserine (PS) is predominately localized in the inner plasma membrane leaflet. During apoptosis, PS relocates to the outer leaflet. Herein, we established PS tumor models with...
30.
Agnihotri P, Mishra A, Agarwal P, Vignali K, Workman C, Vignali D, et al.
J Immunol
. 2022 Sep;
209(8):1586-1594.
PMID: 36104110
Lymphocyte activation gene 3 protein (LAG3; CD223) is an inhibitory receptor that is highly upregulated on exhausted T cells in tumors and chronic viral infection. Consequently, LAG3 is now a...